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588 P. Sobrino-Vegas et al.Cohort study First-year mortality was the highest (aHRLP.vs.nLP Z 10.3[CI95%:5.5e19.3]); between 1 and 4
years post-diagnosis, aHRLP.vs.nLP Z 1.9(1.2e3.0); and >4 years, aHRLP.vs.nLP Z 1.5(0.7e3.1).
First-year’s main cause of death was HIV/AIDS (73%); and malignancies among those surviv-
ing >4 years (32%). HIV/AIDS-related deaths were more likely in LP (59.2% vs. 25.0%;
p < 0.001). LP declined from 55.9% (2004e05) to 39.4% (2012e13), and reduced in 46.1% in
men who have sex with men (MSM) and 37.6% in heterosexual men, but increased in 22.6%
in heterosexual women.
Factors associated with LP: sex (ORMEN.vs.WOMEN Z 1.4[1.2e1.7]); age (OR31e40.vs.<30 Z 1.6
[1.4e1.8], OR41e50.vs.<30 Z 2.2[1.8e2.6], OR>50.vs.<30 Z 3.6[2.9e4.4]); behavior
(ORInjectedDrugUse.vs.MSM Z 2.8[2.0e3.8]; ORHeterosexual.vs.MSM Z 2.2[1.7e3.0]); education
(ORPrimaryEducation.vs.University Z 1.5[1.1e2.0], ORLowerSecondary.vs.University Z 1.3[1.1e1.5]); and
geographical origin (ORSub-Saharan.vs.Spain Z 1.6[1.3e2.0], ORLatin-American.vs.Spain Z 1.4[1.2
e1.8]).
Conclusions: LP is associated with higher mortality, especially short-term- and HIV/AIDS-
related mortality. Mid-term-, but not long-term mortality, remained also higher in LP than
nLP. LP decreased in MSM and heterosexual men, not in heterosexual women. The groups most
affected by LP are low educated, non-Spanish and heterosexual women.
ª 2016 The Authors. Published by Elsevier Ltd on behalf of the The British Infection
Association. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
In Europe and other high-income settings, a high proportion
of HIV diagnoses are made late.1,2 Late diagnosis of HIV
infection is widely acknowledged as a major public health
issue strongly related to increased morbidity and mortal-
ity.2e13 Not only is late presentation (LP) the main reason
for delayed antiretroviral treatment (ART) leading to
poorer patient immune and viral response, but it has
been identified as a key factor in HIV transmission.14
Finally, LP has been linked to more intense use of health-
care resources with the corresponding higher costs.15
Several studies have examined the impact of late HIV
diagnosis on mortality3,4,7,9e11,13; however, most have as-
sessed the effect on short-term mortality3,4,13 or the cumu-
lative effect over a period of time.7,11 In fact, to our
knowledge, there is no previous research on the impact of
LP and clinical stage at diagnosis on short-, mid-, and
long-term mortality. There is also a lack of studies on
how LP relates to different causes of death.
The aim of this work is two-fold. First, we examine the
impact of LP on short-, mid-, and long-term mortality
including cause-specific mortality. Second, we describe
temporal trends of late diagnosis and related risk factors.
Methods
We analyzed data from individuals newly-diagnosed with
HIV between 2004 and 2013. Data came from CoRIS (Spanish
acronym for the AIDS Research Network Cohort). CoRIS is an
open, prospective, multicentre cohort of adult HIV-positive
patients who are ART-na€ıve at study entry. Patients were
followed-up in any of the participating sites after January
2004. Cohort participants were recruited in 33 public
healthcare centres, 32 hospitals, and one HIV/STD clinic.
Sites are distributed across 13 of the 17 regions in Spain. A
detailed description of the cohort’s methodology has been
published elsewhere.16This study was approved by each of the participating
centres’ research ethics committee (see addendum for a
list of participating healthcare sites). Patients signed
written informed consent forms before study entry. The
cohort study meets all the requirements of the latest
legislation (RD1617/11) as a data node of the Spanish HIV
Biobank.Study population
The study population includes all individuals newly-
diagnosed with HIV with available CD4 cell count within 6
months of diagnosis and who were recruited up to the 31st
of May of 2013 (administrative censoring date). We defined
a newly-diagnosed individual as a patient diagnosed with
HIV up to six months before study entry. To ensure that only
newly-diagnosed patients were included, those presenting
an AIDS-defining illness more than 6 months prior to the HIV
diagnosis were excluded.
Based on consensus definitions,17 we defined patients
with late presentation (LP) as those presenting for care
with a CD4 cell count below 350 cells/ml or with an
AIDS-defining event (ADE), and patients with late pre-
sentation with advanced HIV disease (LPAD) as those
presenting for care with a CD4 cell count below
200 cells/ml or with an ADE. Since our study population
is comprised of newly-diagnosed individuals, in our case
LP and late diagnosis are equivalent. In addition to the
aforementioned consensus definition, we used the vari-
able clinical status at HIV diagnosis. This variable de-
termines four mutually exclusive patient groups which
are classified according to the following order of prior-
ity: AIDS present at time of HIV diagnosis; CD4 cell
count <200 cells/ml and AIDS-free; CD4 cell count
200 but <350 cells/ml and AIDS-free, and CD4 cell
count 350 cells/ml and AIDS-free. The first two cate-
gories coincide with LPAD and the first three categories
correspond to LP.
Impact of late presentation HIV in mortality 589Statistical analyses
We compared sociodemographic characteristics among LP
and non-LP (nLP) patients and used multiple logistic
regression models to assess if factors such as sex, age at
HIV diagnosis, transmission category, region of origin, and
educational level were independently associated with LP
(likewise for LPAD). We tested for potential interactions.
The method of multiple imputation by chained equations
(MICE) was used to handle missing values assuming a missing
at random (MAR) pattern.18 An imputation model was
developed for each sex. An ordinal model was used for
educational level and multinomial logistic models for the
rest of the variables. Models included all variables under
analysis plus the response variable. Twenty replicates
were generated, and the final results were calculated ac-
cording to the method described by Little and Rubin.19
Sensitivity analyses were conducted comparing results
from MICE with complete case analyses as well as with
those obtained using an indicator category in variables
with missing values. We described the proportion of LP
(and LPAD) patients by year of HIV diagnosis, testing for
trend. Annual declines were assessed with multiple logistic
regression models adjusted for potential confounding vari-
ables and tested for potential interactions. Results from
these analyses were interpreted based on adjusted Odds
Ratios (aOR) and the corresponding 95% confidence inter-
vals (95%CI).
We assessed how clinical status at HIV diagnosis, LP, or
LPAD impacted survival using multivariate Cox regression
models allowing for a time lag between HIV diagnosis and
study entry. However, because Schoenfeld residuals tests
indicated that the proportional hazards assumption was not
confirmed, an interaction with follow-up time was included
so that the hazards were proportional within each period of
analyses, i.e., <1 year, 1e4 years, and >4 years. In
addition to previously described potential confounders,
year of inclusion in the cohort and ART initiation (defined
as a time-varying variable) were modeled into the analyses.
Crude Hazard Ratios (HR) and adjusted Hazard Ratios (aHR)
with 95%CIs were calculated.
To evaluate the effect of patients lost to follow-up on
mortality estimates, sensitivity analyses were performed
using the Fine and Gray model, where lost to follow-up
were considered as a competing event.20 Causes of death
were coded using a modified cause of death coding protocol
for HIV which is based on the CoDe protocol developed by
the Copenhagen HIV Program (www.cphiv.dk).21
Finally, we estimated confidence intervals using robust
methods that assumed correlations among participants
recruited at each site and independence among partici-
pants recruited at different sites.22
Analyses were conducted using Stata (V.13, Stata Cor-
poration, College Station, Texas, USA).
Results
Of the 9667 patients enrolled in project CoRIS until the 31st
of May of 2013, 7528 (77.8%) were diagnosed with HIV
infection in the 6 months prior to inclusion in the cohort. Of
those, 342 were excluded due to absence of CD4 cell countsmeasured within the first six months post-diagnosis. An
additional 21 individuals with an AIDS-defining event over 6
months before HIV diagnosis were excluded as well. Finally,
a total of 7165 participants were included; most were men
(83.2%), median age was 34 years; 57.9% were men who
have sex with men (MSM) and 32.3% were heterosexually
infected; 38.5% had reached lower secondary education
and 28.6% had university studies; 30.6% were not native to
Spain, of whom 59.3% were from Latin America (LA) and
17.5% from Sub-Saharan Africa (SSA); 10.1% had a positive
serology for hepatitis C virus (HCV) (Table 1).Late presentation and presentation with advanced
HIV disease: magnitude, trends and risk factors
A total of 3359 subjects (46.9%) were LP patients, of which
2047 (28.6%) were LPAD patients, and 1011 (14.1%) had an
AIDS-defining event at time of HIV diagnosis. The remaining
3806 subjects were nLP, our reference category. During the
follow-up, 90.4% of LP patients started ART, with a median
time from HIV diagnosis to ART initiation of 55 days (IQR:
26e112).
Table 1 shows the percentage of LP and LPAD patients
according to their characteristics as well as the results of
multivariate analysis obtained after MICE. Risk factors for
LP were: being male (aOR 1.38 [95%CI: 1.15e1.65]); being
over 30 years of age (aOR31e40 1.59 [95%CI: 1.39e1.82],
aOR41e50 2.18 [95%CI: 1.83e2.60], aOR>50 3.60 [95%CI:
2.92e4.44]); to be an injection drug user (IDU) (aOR 2.78
[95%CI: 2.01e3.84]) or heterosexually infected (aOR 2.21
[95%CI: 1.65e2.95]), versus MSM; lower educational
achievement such as primary school or less (aOR 1.47
[95%CI: 1.12e1.94]) or lower secondary school (aOR 1.29
[95%CI: 1.09e1.52]) versus a university-level education.
Finally, place of origin was also a risk factor. Participants
from SSA (aOR 1.62 [95%CI: 1.32e1.99]) or LA (aOR 1.44
[95%CI: 1.15e1.81]) were at higher risk for LP than Span-
iards. Risk factors for LPAD were very similar to the ones
just described above.
In the period between 2004e05 and 2012e13 the per-
centage of LP decreased from 55.9% to 39.4%. However, the
improvement was not homogeneous across transmission
categories and sex (Fig. 1). Adjusted results for age at diag-
nosis, educational level, and region of origin confirm that
LP annual decline was statistically significant among MSM
(aOR 0.94 [95%CI: 0.88e0.99]) and heterosexual men (aOR
0.94 [95%CI: 0.89e0.99]), but not among heterosexual
women (aOR 1.02 [95%CI: 0.97e1.08]) mainly among non-
Spaniards. Specifically, in this period, the percentages of
LP in MSM and heterosexual men declined 46.1% and
37.6%, respectively, whereas LP in heterosexual women
increased by 22.6%.
Between the years 2004e05 and 2012e13, the propor-
tion of LPAD also saw a reduction from 37.6% down to
21.9%. Regarding changes by transmission risk categories,
LPAD followed the same patterns as described above for LP.
Annual changes in MSM and heterosexual men were signif-
icant (aOR 0.90 [95%CI: 0.83e0.98] and aOR 0.94 [95%CI:
0.88e0.99], respectively). The number of LPAD among
heterosexual women did not vary during the period under
study (aOR 1.00 [95%CI: 0.93e1.07]).
Table 1 Sociodemographic and epidemiological characteristics of study patients and the association with late presentation
(LP) and late presentation with advanced disease (LPAD).
n (%) Late presentation (LP) LP with advanced HIV disease (LPAD)
n (%) aOR (CI 95%) n (%) aOR (CI 95%)
Total 7165 46.9 28.6
Sex
Men 5959 (83.2) 2693 (45.2) 1.38 (1.15e1.65) 1606 (27.0) 1.39 (1.15e1.68)
Women 1206 (16.8) 666 (55.2) 1 441 (36.6) 1
Age at HIV diagnosis
30 years 2448 (34.2) 854 (34.9) 1 395 (16.1) 1
31e40 years 2652 (37.0) 1245 (46.9) 1.59 (1.39e1.82) 747 (28.2) 1.96 (1.60e2.40)
41e50 years 1390 (19.4) 793 (57.1) 2.18 (1.83e2.60) 568 (40.9) 3.15 (2.52e3.96)
>50 years 675 (9.4) 467 (69.2) 3.60 (2.92e4.44) 337 (49.9) 4.35 (3.49e5.43)
Category of transmission
Men who have sex with men 4151 (57.9) 1525 (36.7) 1 768 (18.5) 1
Injecting drug users 470 (6.6) 305 (64.9) 2.78 (2.01e3.84) 209 (44.5) 2.78 (1.93e4.00)
Heterosexuals 2315 (32.3) 1373 (59.3) 2.21 (1.65e2.95) 955 (41.3) 2.56 (1.88e3.48)
Others 80 (1.1) 54 (67.5) 2.97 (1.72e5.12) 42 (52.5) 3.87 (2.40e6.25)
Unknown 149 (2.1) 102 (68.5) e 73 (49.0) e
Educationa
Primary school or less 497 (8.3) 307 (61.8) 1.47 (1.12e1.94) 207 (41.6) 1.69 (1.33e2.13)
Lower secondary 1797 (30.2) 994 (55.3) 1.29 (1.09e1.52) 666 (37.1) 1.55 (1.30e1.85)
Upper secondary 1956 (32.9) 824 (42.1) 1.02 (0.89e1.17) 490 (25.1) 1.21 (1.06e1.37)
University 1703 (28.6) 644 (37.8) 1 312 (18.3) 1
Unknown 1212 590 (48.7) e 372 (30.7) e
Origin
Spain 4967 (69.4) 2235 (45.0) 1 1336 (26.9) 1
Western Europe 198 (2.8) 79 (39.9) 0.84 (0.68e1.02) 48 (24.2) 0.93 (0.68e1.27)
Eastern Europe 168 (2.3) 77 (45.8) 1.02 (0.72e1.44) 47 (28.0) 1.13 (0.79e1.62)
Sub-Saharan Africa 384 (5.4) 245 (63.8) 1.62 (1.32e1.99) 170 (44.3) 1.61 (1.31e1.99)
Latin America 1302 (18.2) 642 (49.3) 1.44 (1.15e1.81) 394 (30.3) 1.54 (1.27e1.86)
Others 142 (2.0) 79 (55.6) 1.33 (0.90e1.96) 51 (35.9) 1.32 (0.90e1.94)
Unknown 4 2 (50.0) e 1 (25.0) e
aOR (CI 95%): adjusted Odds Ratio and confidence intervals 95%.
a Lower secondary: ISCED97-2; Upper secondary: ISCED97 3-4; ISCED97 refers to the 1997 International Standard Classification of Ed-
ucation (http://www.unesco.org/education/information/nfsunesco/doc/isced_1997.htm).
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Figure 1 Progression of late presentation prevalence by category of transmission.
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Impact of late presentation HIV in mortality 591Impact of LP on mortality: short-, mid- and long-
term effects
Of the 7165 participants completing the baseline, we
collected at least some follow-up data for 6956 (97.1%),
the equivalent of 23,820 person-years (py) observation. The
median follow-up was 3.1 years (IQR: 1.2e5.3). There were
240 deaths, with a death rate of 1.01 (95%CI: 0.89e1.14)
per 100 py. This rate increased as clinical status worsened
and it was substantially and significantly higher in LP
patients (1.71 vs. 0.31 per 100 py; p < 0.001) (Table 2).
Fig. 2 shows the survival curves by clinical status at HIV
diagnosis. Table 2 illustrates the impact of LP and clinical
status at HIV diagnosis on all-cause mortality. Using nLP
as reference group our results show that during the first
year post-HIV diagnosis LP is associated with a high risk of
early death. The risk increases as clinical status worsens
(aHR200  CD4 < 350 2.8 [95%CI: 1.5e5.4]; aHRCD4  200 5.6
[95%CI: 2.7e11.9]; and aHRAIDS 22.6 [95%CI: 11.5e44.6]).
The prognostic effect of LP and clinical status at HIV diag-
nosis in the mid-term persists but is significantly lessened
(aHR200  CD4 < 350 1.4 [95%CI: 0.7e2.8]; aHRCD4 < 200 1.5
[95%CI: 0.9e2.4]; aHRAIDS 3.0 [95%CI: 1.8e5.0]).
Among participants followed for over 4 years post-
diagnosis, LP and LPAD increase mortality risk (aHR 1.5
[95%CI: 0.7e3.1] and 1.7 [95%CI: 0.8e3.8], respectively)
although these effects fail to reach statistical significance
(Table 2).
LP and causes of death
We have information on cause of death for 207 out of 240
deceased. There were 123 deaths during the first year post-
diagnosis, 73.2% of them were HIV/AIDS-related, 8.9% were
liver-disease related, 7.3%weremalignancy-related, and 5.7%
wereduetoother infectiousdiseases.Amongparticipantswith
LP, HIV/AIDS-related causes represented 74.6% of all deaths,
but only 40.0% of deaths among those with nLP (p < 0.013)
(Fig. 3). Liver- and malignancy-related deaths were more
frequent among nLP than LP (Liver-related: 40.0% nLP
vs.7.6% LP; malignancy-related: 20.0% nLP vs.6.8% LP).
We recorded 59 deaths during the period between the
end of the first year and the fourth year post-HIV diagnosis.
About one third (32.2%) were HIV/AIDS-related (34.9% LP
vs. 25.0% nLP); 25.4% were due to malignancies (27.9% LP
vs. 18.8% nLP); 15.3% were due to other infectious diseases
(11.6% LP vs. 25.0% nLP), and 5.1% were liver-related
deaths (7.0% LP vs. 0% nLP).
Finally, malignancies were the most common cause of
death among the 25 patients who passed away over 4 years
post-HIV diagnosis (32.0% overall; 38.9% LP vs. 14.3% nLP).
Liver-related deaths were the second most common cause
(20.0% overall; 22.2% LP vs. 14.3% nLP), followed by HIV/
AIDS-related conditions (16.0% overall; 16.7% LP vs. 14.3%
nLP) and other infectious diseases (16.0% overall; 11.1% LP
vs. 28.6% nLP).
Sensitivity analyses
We conducted sensitivity analyses to assess the missing
data imputation method used to estimate factorsassociated with LP or LPAD and to estimate the effects of
lost-to-follow up in mortality analyses. Results were similar
to those reported here (data not shown).Discussion
Compared to other HIV patients, the mortality risk of
individuals with a late HIV diagnosis is 10-fold during the
first year after diagnosis and two-fold between the first and
fourth year post-diagnosis. Early mortality among patients
with late diagnosis tends to be HIV/AIDS-related whereas
for those with timely diagnoses liver- and malignancy-
related deaths are more likely causes. In our cohort, almost
half of the individuals newly-diagnosed with HIV between
2004 and 2013 were patients with late presentation and
almost one third were exhibited late presentation with
advanced disease. Although the proportion of LP has
declined in men sexually-infected (MSM and heterosexual),
LP could be increasing among heterosexual women.
The mortality rate in our cohort is comparable to that
observed in other European studies2,11,23,24 but much lower
than in non-European countries.5 As mentioned earlier, de-
layed HIV diagnosis is a major prognostic factor.4,5,10,11,13
This is especially true regarding premature and HIV/AIDS-
related mortality, as shown here. In our cohort, 71% of
deaths of patients with late presentation and who died
within one year of diagnosis were due to HIV/AIDS. Causes
of death among those with LP who survived more than 4
years post-diagnosis were more likely to be liver-related
and non-AIDS defining malignancies; thus resembling causes
of death in individuals with timely diagnoses, those in other
cohorts with long follow-up times,24 or in patients undergo-
ing ART treatment.25 For patients presenting with an AIDS
diagnosis, the likelihood of an early death is especially
high as their mortality risk is 20 times greater during the
first year post-diagnosis and 3 times greater between the
first and fourth year post-diagnosis compared to their
timely-diagnosed counterparts. Given that the death rate
of patients with timely HIV diagnosis was 0.31 per 100 py,
had all our participants been diagnosed sooner, 74 deaths
would have been avoided and mortality would have been
reduced by 69%.
Although the majority of patients with LP began ART
immediately after HIV diagnosis, ART is not effective
enough to eliminate the excess mortality related to LP, at
least not during the first year post-diagnosis. However, we
believe that ART is responsible for significantly attenuating
the impact of LP on mortality overtime.25,26 Among those
LP patients that did not start ART, 10% died in the first three
months after the diagnosis. The reason for them not start-
ing ART could be they were considered too sick to benefit
from it. One out of four patients who did not start ART,
their follow-up was lower than a month since diagnosis.
The prevalence of LP and LPAD in our cohort is very
similar to that reported by the Spanish National Surveil-
lance System of New HIV Diagnoses (SINIVIH for its
Spanish acronym),27,28 and other European studies which
report a LP prevalence between 45% and 63%.6,10,23,29e32
In our cohort, and throughout the period under study, the
percentages of LP by transmission category have evolved
differently. LP has experienced substantial declines
Table 2 Impact of late presentation and clinical status at HIV diagnosis on mortality. Overall mortality rates. Results of survival analysis and Cox regression model for follow-
up periods.
Overall results Results for follow-up periods
First year since diagnosis 1e4 years Since diagnosis >4 years since diagnosis
Deaths p-y Rate (95%CI) N at risk Deaths aHR(*)
(95%CI)
N at risk Deaths aHR(*)
(95CI%)
N at risk Deaths aHR(*)
(95CI%)
Total 240 23,820 1.01 (0.89e1.14) 6956 132 5511 72 2840 36
Late presentation
nLP 37 11,921 0.31 (0.22e0.43) 3666 8 1 2923 19 1 1378 10 1
LP 203 11,900 1.71 (1.49e1.96) 3290 124 10.3
(5.5e19.3)
2588 53 1.9
(1.2e3.0)
1462 26 1.5
(0.7e3.1)
LPAD 176 7564 2.33 (2.00e2.70) 2010 114 14.5 (**)
(7.4e28.3)
1578 41 2.2 (**)
(1.4e3.5)
952 21 1.7 (**)
(0.8e3.8)
Clinical status at HIV diagnosis
AIDS 132 3817 3.46 (2.92e4.10) 999 94 22.6
(11.5e44.6)
769 28 3.0
(1.8e5.0)
476 10 1.5
(0.5e4.4)
CD4 < 200 e AIDS-free 44 3747 1.17 (0.87e1.58) 1011 20 5.6
(2.7e11.9)
809 13 1.5
(0.9e2.4)
476 11 1.9
(0.9e4.0)
200  CD4 < 350 e AIDS-free 27 4335 0.62 (0.43e0.91) 1280 10 2.8
(1.5e5.4)
1010 12 1.4
(0.7e2.8)
510 5 1.1
(0.4e2.7)
CD4  350 e AIDS-free 37 11,921 0.31 (0.22e0.43) 3666 8 1 2923 19 1 1378 10 1
(*) aHR (CI 95%): adjusted Hazard Ratios by category of transmission-sex and age at HIV diagnosis and confidence intervals 95%.
(**) Reference category: Subjects not LPAD (CD4  200 and AIDS-free).
592
P.
So
b
rin
o
-V
e
ga
s
e
t
a
l.
Figure 2 Kaplan Meier survival analysis according to clinical status at the time of HIV diagnosis.
Impact of late presentation HIV in mortality 593among MSM and heterosexual men, 50% and 40% respec-
tively. However, heterosexual women have not
benefitted from this improvement, if fact, we observed
a slight increase (23%), although it did not reach statisti-
cal significance. However, this upward tendency is
consistent with increasing rates of LP among other South
European women.2 In general, women tend to be under-
represented in clinical trials and epidemiological studies
on HIV except those concerning vertical transmission pre-
vention. Thus, there is a substantial gap of knowledge
when it comes to issues related to HIV diagnosis in
women.33
Our current results regarding LP are consistent with
previous work published by our group based on this same
cohort,13 and by other authors.2,6,10,29e32,34,35 Finally, our
analyses by region of origin determined that LP was more0%
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Figure 3 Causes of death distribution according to late presente
diagnosis.prevalent among patients from Sub-Saharan Africa and
Latin America than among Spaniards, confirming the well-
documented excess prevalence of delayed HIV diagnoses
among migrant populations in Spain and other European
countries.2,6,10,29,30,32
The nation-wide evidence presented in this work
strengthens and adds support for further intensifying HIV
testing efforts in Spain and covering larger segments of the
population by facilitating access to the test. Our data
provide strong backing to the Ministry of Health’s recom-
mendation to offer HIV testing in primary care as a strategy
to reduce the burden of LP,36 especially in heterosexual
women. Similarly, granting undocumented migrants access
to primary care is highly likely to make a dent in the high
rates of delayed diagnoses among populations from other
countries.nLP (16) LP (43) nLP (7) LP (18)
1-4 years since
diagnosis
> 4 years since
diagnosis
Liver InfecƟous Others
rs (LP) or not late presenters (nLP) and time elapsed since HIV
594 P. Sobrino-Vegas et al.One of the strengths of the study is being based on
CoRIS, a large national cohort representative of the
epidemiological situation of HIV-infected individuals in
Spain.
Our results should be interpreted in the context of the
study’s limitations. First, we were not able to include all
new HIV diagnoses in our analysis because 4.6% of cases
lack the CD4 cell count information at time of diagnosis.
Missing data were less likely among MSM and among
individuals with higher education. Another potential bias
affecting mortality results is introduced by patients lost to
follow-up. However, there are three indications that our
results may not have been affected significantly by these
biases. First, the favorable results from our sensitivity
analyses; second, patients lost to follow-up had better
clinical characteristics at study entry16 than the rest; and,
finally, the percentages of lost to follow-up were similar
across LP groups. In addition, the project has a protocol
in place to facilitate the inclusion of patients dying shortly
after their first arrival to the hospital and before having a
chance to sign the study’s informed consent form. In these
cases of early death, we collect basic anonymized data. Un-
fortunately, the unreliable implementation of this partic-
ular protocol may have led us to underestimate early
mortality among late presenters.
In conclusion, individuals with a late HIV diagnosis
experience higher mortality, especially within the first
year post-diagnosis and mostly due to HIV/AIDS-related
causes. Non-HIV/AIDS-related causes of death, such as
liver- and malignancy-related disease, reach substantial
percentages only among individuals who were diagnosed
with HIV in a timely fashion.
The proportion of patients with late HIV diagnosis
remains unacceptably high in a European country with a
large public healthcare system. And further, despite the
decline in LP among most groups, heterosexual women have
not benefitted from this improvement which requires
further investigation.
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